Company Monitoring Page for Novartis

latest headlines for company on cafepharma

Novartis set to take on Roche as FDA clears first at-home, injectable MS drug
Biopharma Dive
Thu, 08/20/20 - 10:52 pm
Tags:
Novartis, FDA, Kesimpta, ofatumumab, MS, multiple sclerosis
Regeneron flashes ‘great advance' in the NEJM for that other cholesterol drug sitting at the FDA
Endpoints
Wed, 08/19/20 - 11:45 pm
Tags:
Regeneron, inclisiran, RNAi, Novartis, New England Journal of Medicine
U.S. court upholds patent for Novartis MS drug Gilenya
Reuters
Tue, 08/18/20 - 11:04 am
Tags:
Novartis, patents, Gilenya, MS, multiple sclerosis
These 4 Drugmakers Are Using AI to Improve Their Products. Does It Make Them Better Buys?
Motley Fool
Sun, 08/16/20 - 10:40 pm
Tags:
artificial intelligence, drug development, AstraZeneca, GSK, Novartis, Eli Lilly
Five Top Drugmakers Reveal List vs. Net Price Gaps
Drug Channels
Tue, 08/11/20 - 01:17 pm
Tags:
Eli Lilly, Janssen, Merck, Novartis, Sanofi, drug pricing
Novartis says CAR-T cancer therapy works in second lymphoma type
BioPharma Dive
Tue, 08/4/20 - 12:40 pm
Tags:
Novartis, Kymriah, follicular lymphoma, CAR-T
Novartis’ Ilaris unexpectedly slashes need for joint replacements from osteoarthritis in key study
Fierce Biotech
Mon, 08/3/20 - 11:45 pm
Tags:
Novartis, Ilaris, osteoarthritis, joint replacements
Sangamo and Novartis Enter Agreement to Focus on Neurodevelopmental Diseases
BioSpace
Thu, 07/30/20 - 11:23 pm
Tags:
Novartis, Sangamo Therapeutics, gene regulation therapies, autism, neurodevelopmental disorders
Go or no go? Valuable drugs set for FDA decisions
EP Vantage
Wed, 07/29/20 - 10:54 am
Tags:
FDA, drug approvals, Novartis, inclisiran, Biomarin, valrox, Roche, risdiplam, GSK, belantamab mafodotin, Gilead Sciences, Galapagos, filgotinib
Novartis announces phase III study of Jakavi in chronic graft-versus-host disease met primary and key secondary endpoints
Pharmaceutical Business Review
Tue, 07/28/20 - 10:30 am
Tags:
Novartis, graft vs host disease, Jakavi
Sandoz earmarks $175M to upgrade tech at European hub for antibiotics manufacturing
BioPharma Dive
Mon, 07/27/20 - 11:05 pm
Tags:
Novartis, Sandoz, Europe, antibiotics, drug manufacturing
Former Novartis sales rep gets $109M for blowing the whistle on doctor kickbacks
Fierce Pharma
Fri, 07/24/20 - 09:29 am
Tags:
Novartis, kickbacks, whistleblowers, whistleblower lawsuits, drug reps
Ruxolitinib passes another PhIII test for graft-versus-host disease, a win for Incyte and Novartis
Endpoints
Thu, 07/23/20 - 11:06 am
Tags:
ruxolitinib, Novartis, Incyte, graft vs host disease
Novartis introduces inflammatory villain in its first Xiidra dry eye DTC campaign
Fierce Pharma
Thu, 07/23/20 - 10:51 am
Tags:
Novartis, Xiidra, DTC advertising, dry eye disease
Novartis dumps Ziarco eczema drug, taking $485M hit
Fierce Biotech
Tue, 07/21/20 - 10:51 am
Tags:
Novartis, eczema, Ziarco, M&A, ZPL389
Novartis profit slips as stockpiling reverses
Marketwatch
Tue, 07/21/20 - 10:49 am
Tags:
Novartis, earnings
Biogen to launch Phase IV study of spinal muscular atrophy drug in post-gene therapy patients
MedCity News
Tue, 07/21/20 - 10:37 am
Tags:
Biogen, clinical trials, Spinraza, Novartis, Zolgensma, SMA, spinal muscular atrophy
10 most valuable R&D projects in the pharmaceutical industry pipeline
Beckers Hospital Review
Mon, 07/20/20 - 11:49 pm
Tags:
R&D, drug development, Eli Lilly, Novartis, Argenx, Bristol-Myers Squibb, Vir Biotechnolgy, Biogen, GSK, Iovance, Roche
Eli Lilly’s Mirikizumab Hits the Mark in Phase III Study, Bests Cosentyx
BioSpace
Sat, 07/18/20 - 12:17 pm
Tags:
Eli Lilly, psoriasis, mirikizumab, clinical trials, Cosentyx, Novartis
Novartis to provide 'no profit' COVID-19 drugs to low income countries
Reuters
Thu, 07/16/20 - 11:00 am
Tags:
Novartis, Sandoz, non-profits, developing countries, generics

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.